Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-04
DOI
10.1111/cas.15984
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
- (2022) Theodora A. Constantin et al. ONCOGENE
- Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
- (2022) Fanying Tang et al. SCIENCE
- Androgen receptor mutations for precision medicine in prostate cancer
- (2022) Masaki Shiota et al. ENDOCRINE-RELATED CANCER
- Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer
- (2021) XinTao Gao et al. Molecular Oncology
- CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
- (2021) Abel Tesfaye Anshabo et al. Frontiers in Oncology
- ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
- (2021) Zhe Tang et al. CLINICAL CANCER RESEARCH
- An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
- (2021) Alastair Davies et al. NATURE CELL BIOLOGY
- Reversible phosphorylation of cyclin T1 promotes assembly and stability of P-TEFb
- (2021) Fang Huang et al. eLife
- Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer
- (2020) Milly J. McAllister et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Promoter-Level Transcriptome Identifies Stemness Associated With Relatively High Proliferation in Pancreatic Cancer Cells
- (2020) Ru Chen et al. Frontiers in Oncology
- Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
- (2020) Xiangnan Guan et al. CLINICAL CANCER RESEARCH
- Characterizing CDK12-Mutated Prostate Cancers
- (2020) Pasquale Rescigno et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
- (2020) Nicole Brighi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of modules and functional analysis in CRC subtypes by integrated bioinformatics analysis
- (2019) Ru Chen et al. PLoS One
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer
- (2018) Joshua W. Russo et al. CANCER LETTERS
- Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
- (2018) Qiuhui Li et al. Nature Communications
- HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase
- (2017) Abhishek A. Chakraborty et al. Science Translational Medicine
- Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis
- (2016) Timothy E. Newhook et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting CDK9: a promising therapeutic opportunity in prostate cancer
- (2016) Muhammed H Rahaman et al. ENDOCRINE-RELATED CANCER
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
- (2016) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
- (2016) Yogesh A. Sonawane et al. JOURNAL OF MEDICINAL CHEMISTRY
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
- (2015) K. Chi et al. ANNALS OF ONCOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Sequencing of agents in castration-resistant prostate cancer
- (2015) David Lorente et al. LANCET ONCOLOGY
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
- (2014) E. J. Chen et al. CLINICAL CANCER RESEARCH
- Androgen receptor phosphorylation: biological context and functional consequences
- (2014) Yulia Koryakina et al. ENDOCRINE-RELATED CANCER
- Colony-stimulating factor 1 potentiates lung cancer bone metastasis
- (2014) Jaclyn Y Hung et al. LABORATORY INVESTIGATION
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- A promoter-level mammalian expression atlas
- (2014) NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
- (2012) Naomi L. Sharma et al. CANCER CELL
- Androgen Receptor Serine 81 Phosphorylation Mediates Chromatin Binding and Transcriptional Activation
- (2012) Shaoyong Chen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5
- (2011) Fu-Ning Hsu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Activation of Rac1 Is Closely Related to Androgen-Independent Cell Proliferation of Prostate Cancer Cells Bothin Vitroandin Vivo
- (2010) Takashi Kobayashi et al. MOLECULAR ENDOCRINOLOGY
- CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation
- (2010) Vicki Gordon et al. MOLECULAR ENDOCRINOLOGY
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
- (2009) Qianben Wang et al. CELL
- The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
- (2008) Sonja Baumli et al. EMBO JOURNAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now